Clinical trials testing the specific question of whether intermittent dosing may be beneficial for pediatric glioma patients are underway; NCT03326388 (INSPECT) is a phase I/II study in children with NF1-associated tumors (inoperable plexiform neurofibromas and recurrent optic pathway gliomas) being treated with intermittent dosing of selumetinib. The gene discussed is NF1; the disease is glioma.